Abstract:In this study, we described a series of 2,8-diazaspiro[4.5]decan-1-one derivatives as selective TYK2/JAK1 inhibitors. Systematic exploration of the structure–activity relationship through the introduction of spirocyclic scaffolds based on the reported selective TYK2 inhibitor 14l led to the discovery of the superior derivative compound 48. Compound 48 showed excellent potency on TYK2/JAK1 kinases with IC50 values of 6 and 37 nM, respectively, and exhibited more than 23-fold selectivity for JAK2. Compound 48 also demonstrated excellent metabolic stability and more potent anti-inflammatory efficacy than tofacitinib in acute ulcerative colitis models. Moreover, the excellent anti-inflammatory effect of compound 48 was mediated by regulating the expression of related TYK2/JAK1-regulated genes, as well as the formation of Th1, Th2, and Th17 cells. Taken together, these findings suggest that compound 48 is a selective dual TYK2/JAK inhibitor, deserving to be developed as a clinical candidate.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01137.Listing the metabolic stability of the preferred compounds (Table S1); listing binding affinities of 48 with 110 protein kinases (Table S2); listing the disease activity index (DAI) scoring system (Table S3); listing the IL-6, TNF-α, and IL-10 concentrations in Serum of UC Mice (Table S4); listing the primer sequence (Table S5); listing the docking results of compounds 48, 8, and 11 (Figure S1); listing the inhibition patterns of compound 48 and different drugs on different phosphorylated STATs (Figure S2); listing the relative gray quantitative analysis of p-STATs after treatment of 48 (Figure S3); listing the inhibitory effect of compound 48 on the p-STAT3 after cytokine stimulation (Figure S4); listing the in vivo assays of tissue distribution mice (Figure S5); listing the HE staining of heart, liver, spleen, lungs, and kidneys (Figure S6); listing the detection of levels of proteins in the colon tissue of UC mice by western blot (Figure S7); listing the effect of 48 on the expression of Th1, Th2, and Th17 cells (Figure S8); listing the HPLC of compounds 8, 33, 41, 48, and 49, respectively (Figures S9–S13); listing F-NMR spectra of compound 48 (Figure S14) (PDF)jmcmar_mfs (CSV)Compound 48-JAK1-6DBN (PDB)Compound 48-TYK2-6DBK (PDB)Compound 8-JAK1-6DBN (PDB)Compound 8-TYK2-6DBK (PDB)Compound 11-JAK1-6DBN (PDB)Compound 11-TYK2-6DBK (PDB)This article has not yet been cited by other publications.

Structure-based Discovery of 1H-Indole-2-carboxamide Derivatives As Potent ASK1 Inhibitors for Potential Treatment of Ulcerative Colitis.

Design, Synthesis and Biological Evaluation of 1H-Indazole Derivatives As Novel ASK1 Inhibitors.

Discovery of pyrimidine-5-carboxamide derivatives as novel salt-inducible kinases (SIKs) inhibitors for inflammatory bowel disease (IBD) treatment

Identification, Structure–Activity Relationships of Marine-Derived Indolocarbazoles, and a Dual PKCθ/δ Inhibitor with Potent Antipancreatic Cancer Efficacy

Discovery of First-in-Class TAK1-MKK3 Protein-Protein Interaction (PPI) Inhibitor (R)-STU104 for the Treatment of Ulcerative Colitis Through Modulating TNF-α Production.

Discovery of Potent Apoptosis Signal-Regulating Kinase 1 Inhibitors Via Integrated Computational Strategy and Biological Evaluation

Synthesis and biological evaluation of quinoxaline derivatives as ASK1 inhibitors

Discovery of a Series of 4-Amide-thiophene-2-carboxyl Derivatives As Highly Potent P2Y14 Receptor Antagonists for Inflammatory Bowel Disease Treatment

Discovery of Novel Imidazo[4,5- c ]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis

Discovery of 6‐Acylamino/Sulfonamido Benzoxazolone with IL‐6 Inhibitory Activity as Promising Therapeutic Agents for Ulcerative Colitis

Discovery of 3-(4-(2-((1h-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile Derivatives As Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease

Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease

Discovery of Novel Sesquiterpene Lactone Derivatives as Potent PKM2 Activators for the Treatment of Ulcerative Colitis

Design,Synthesis and Biological Evaluation of Potent and Selective S1PR1 Agonists for the Treatment of Ulcerative Colitis

Discovery of ( Z )-1-(3-((1 H -Pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)-3-(isoxazol-3-yl)urea Derivatives as Novel and Orally Highly Effective CSF-1R Inhibitors for Potential Colorectal Cancer Immunotherapy

A Novel CDK8 Inhibitor with Poly-Substituted Pyridine Core: Discovery and Anti-Inflammatory Activity Evaluation in Vivo

Identification of novel indolinone derivatives as CTSC inhibitors to treat inflammatory bowel disease by modulating inflammatory factors

Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8 Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease In Vivo .

Discovery and Optimization of Novel <i>h</i>DHODH Inhibitors for the Treatment of Inflammatory Bowel Disease

Computer-aided molecular design and optimization of potent inhibitors disrupting APC‒Asef interaction

Novel Hydrogen Sulfide Hybrid Derivatives of Keap1-Nrf2 Protein–Protein Interaction Inhibitor Alleviate Inflammation and Oxidative Stress in Acute Experimental Colitis